Download
s40266-023-01065-x.pdf 855,34KB
WeightNameValue
1000 Titel
  • Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer’s Disease and Parkinson’s Dementia: Systematic Review and Meta-Analysis
1000 Autor/in
  1. Bittner, Nadine |
  2. Funk, Cleo S. M. |
  3. Schmidt, Alexander |
  4. Bermpohl, Felix |
  5. Brandl, Eva J. |
  6. Algharably, Engi E. A. |
  7. Kreutz, Reinhold |
  8. Riemer, Thomas |
1000 Verlag Springer International Publishing
1000 Erscheinungsjahr 2023
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-09-08
1000 Erschienen in
1000 Quellenangabe
  • 40(11):953-964
1000 Copyrightjahr
  • 2023
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40266-023-01065-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600312/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background: The acetylcholinesterase inhibitors (AChEIs) donepezil, galantamine, and rivastigmine are commonly used in the management of various forms of dementia. Objectives: While these drugs are known to induce classic cholinergic adverse events such as diarrhea, their potential to cause psychiatric adverse events has yet to be thoroughly examined. Methods: We sought to determine the risk of psychiatric adverse events associated with the use of AChEIs through a systematic review and meta-analysis of double-blind randomized controlled trials involving patients with Alzheimer's dementia and Parkinson's dementia. Results: A total of 48 trials encompassing 22,845 patients were included in our analysis. Anorexia was the most commonly reported psychiatric adverse event, followed by agitation, insomnia, and depression. Individuals exposed to AChEIs had a greater risk of experiencing appetite disorders, insomnia, or depression compared with those who received placebo (anorexia: odds ratio [OR] 2.93, 95% confidence interval [CI] 2.29-3.75; p < 0.00001; decreased appetite: OR 1.93, 95% CI 1.33-2.82; p = 0.0006; insomnia: OR 1.55, 95% CI 1.25-1.93; p < 0.0001; and depression: OR 1.59, 95% CI 1.23-2.06, p = 0.0004). Appetite disorders were also more frequent with high-dose versus low-dose therapy. A subgroup analysis revealed that the risk of insomnia was higher for donepezil than for galantamine.Conclusions Our findings suggest that AChEI therapy may negatively impact psychological health, and careful monitoring of new psychiatric symptoms is warranted. Lowering the dose may resolve some psychiatric adverse events, as may switching to galantamine in the case of insomnia.
1000 Sacherschließung
lokal Systematic Review
lokal Cholinesterase Inhibitors/adverse effects [MeSH]
lokal Anorexia/drug therapy [MeSH]
lokal Humans [MeSH]
lokal Alzheimer Disease/drug therapy [MeSH]
lokal Donepezil [MeSH]
lokal Sleep Initiation and Maintenance Disorders/chemically induced [MeSH]
lokal Anorexia/chemically induced [MeSH]
lokal Parkinson Disease/drug therapy [MeSH]
lokal Randomized Controlled Trials as Topic [MeSH]
lokal Rivastigmine/therapeutic use [MeSH]
lokal Medical and Health Sciences
lokal Galantamine/therapeutic use [MeSH]
lokal Acetylcholinesterase/therapeutic use [MeSH]
lokal Sleep Initiation and Maintenance Disorders/drug therapy [MeSH]
lokal Phenylcarbamates/adverse effects [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Qml0dG5lciwgTmFkaW5l|https://frl.publisso.de/adhoc/uri/RnVuaywgQ2xlbyBTLiBNLg==|https://frl.publisso.de/adhoc/uri/U2NobWlkdCwgQWxleGFuZGVy|https://frl.publisso.de/adhoc/uri/QmVybXBvaGwsIEZlbGl4|https://frl.publisso.de/adhoc/uri/QnJhbmRsLCBFdmEgSi4=|https://frl.publisso.de/adhoc/uri/QWxnaGFyYWJseSwgRW5naSBFLiBBLg==|https://frl.publisso.de/adhoc/uri/S3JldXR6LCBSZWluaG9sZA==|https://orcid.org/0000-0002-8068-3192
1000 Hinweis
  • DeepGreen-ID: 8a366a1ca8d7454ba66be3e107ff9fe0 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Charité – Universitätsmedizin Berlin |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Charité – Universitätsmedizin Berlin |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6488176.rdf
1000 Erstellt am 2024-10-03T10:22:30.553+0200
1000 Erstellt von 322
1000 beschreibt frl:6488176
1000 Zuletzt bearbeitet 2025-08-13T22:13:36.654+0200
1000 Objekt bearb. Wed Aug 13 22:13:36 CEST 2025
1000 Vgl. frl:6488176
1000 Oai Id
  1. oai:frl.publisso.de:frl:6488176 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source